High Risk Neuroblastoma
Investigators: Carlos Morales Betanzos
Collaborators: Francis Eshun, M.D. and David Carpentieri, M.D. (Phoenix Children’s Hospital) and Konstantinos Petritis, Ph.D. (Translational Genomics Research Institute)
|Who gets it?
What are the symptoms?
|How do we detect it now?
How is it currently treated?
|What are the current challenges?|
To identify new possible treatments for high risk neuroblastoma, we are exploring a protein called ShcC that is expressed in high risk, but not low risk, neuroblastomas with the idea that by better understanding how this protein functions we can develop treatments that target this disease. To do this, we are collaborating with Dr. Petritis at T-Gen to use mass spectroscopy to identify post-transcriptional modifications of ShcC that may activate the protein and contribute to the pathogenesis of the disease.